Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sector Investor who wrote (650)	12/22/1997 2:50:00 PM
From: Czechsinthemail	of 887

Michael King's comments on the side effects profile being skewed unfairly against DepoCyt were discussed by management during the conference call. They indicated that incidence of arachnoiditis were reduced by using steroids, but also that there may have been a reporting bias in noting virtually every detail on the experimental drug and possibly overlooking known side effects in the methotrexate group. Hopefully, DEPO will be able to establish both the efficacy of DepoCyt through larger numbers and the ability of steroids to moderate the side effects profile. For now, I think the assumption of a higher toxicity profile for DepoCyt compared with methotrexate remains uncertain. Baird

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next